



Published in final edited form as:

Exp Gerontol. 2016 August ; 81: 1–7. doi:10.1016/j.exger.2016.04.002.

The relationship between mitochondrial function and walking performance in older adults with a wide range of physical function

Adam J. Santanasto^a, Paul M. Coen^{d,1}, Nancy W. Glynn^a, Kevin E. Conley^c, Sharon A. Jubrias^c, Francesca Amati^{b,2}, Elsa S. Strotmeyer^a, Robert M. Boudreau^a, Bret H. Goodpaster^{b,1}, and Anne B. Newman^{a,*}

^aCenter for Aging and Population Health, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, United States

^bDivision of Endocrinology and Metabolism, School of Medicine, University of Pittsburgh, Pittsburgh, United States

^cTranslational Center for Metabolic Imaging, University of Washington, Seattle, United States

^dDepartment of Health and Physical Activity, School of Education, University of Pittsburgh, Pittsburgh, United States

Abstract

Background—Age related declines in walking performance may be partly attributable to skeletal muscle mitochondrial dysfunction as mitochondria produce over 90% of ATP needed for movement and the capacity for oxidative phosphorylation decreases with age.

Methods—Participants were from two studies: an ancillary to the Lifestyle Interventions and Independence for Elders (LIFE) Study ($n = 33$), which recruited lower functioning participants (Short Physical Performance Battery [SPPB], 7.8 ± 1.2), and the Study of Energy and Aging-Pilot (SEA, $n = 29$), which enrolled higher functioning (SPPB, 10.8 ± 1.4). Physical activity was measured objectively using the Actigraph accelerometer (LIFE) and SenseWear Pro armband (SEA). Phosphocreatine recovery following muscle contraction of the quadriceps was measured using ³¹P magnetic resonance spectroscopy and ATP_{max} (mM ATP/s) was calculated. Walking performance was defined as time (s) to walk 400 m at a usual-pace. The cross-sectional association between mitochondrial function and walking performance was assessed using multivariable linear regression.

Results—Participants were 77.6 ± 5.3 years, 64.2% female and 67.2% white. ATP_{max} was similar in LIFE vs. SEA (0.52 ± 0.14 vs. 0.55 ± 0.14 , $p = 0.31$), despite different function and activity levels (1.6 ± 2.2 vs. 77.4 ± 73.3 min of moderate activity/day, $p < 0.01$). Higher ATP_{max}

*Corresponding author at: 130 DeSoto Street, A527 Crabtree Hall, Pittsburgh, PA 15261, United States. newmana@edc.pitt.edu, kileyem@edc.pitt.edu (A.B. Newman).

¹Current affiliation for Drs. Goodpaster and Coen: Translational Research Institute for Metabolism and Diabetes | Sanford Burnham, Orlando, USA

²Current affiliation for Dr. Amati: University of Lausanne, Switzerland

Disclosures

The authors have no conflicts of interest to disclose.

was related to faster walk-time in SEA ($r^2 = 0.19$, $p = 0.02$); but not the LIFE ($r^2 < 0.01$, $p = 0.74$) cohort.

Conclusions—Mitochondrial function was associated with walking performance in higher functioning, active older adults, but not lower functioning, sedentary older adults.

Keywords

Mitochondrial Function; Mobility; Aging; Muscle; Physical Performance; Walking Performance

1. Introduction

Walking performance decreases significantly with age, but with considerable individual variation (Newman et al., 2009). The underlying causes of age-related slowing are of great interest as slower gait is an independent risk factor for institutionalization (Hornyak et al., 2012) and mortality (Studenski et al., 2011). The role of skeletal muscle in slowing walking performance is still unclear, as sarcopenia only modestly predicts mobility maintenance (or loss) in older adults (Janssen, 2006). Further, maximum aerobic capacity (VO_{2peak}) decreases with age independent of lean mass and physical activity levels (Fleg et al., 2005). VO_{2peak} is partly dependent on the ability of skeletal muscle mitochondria to produce adenosine triphosphate (ATP) and mitochondria produce over 90% of ATP needed for movement (Rolfe and Brown, 1997). The capacity for mitochondrial oxidative phosphorylation is lower in aged compared to younger skeletal muscle, as both mitochondrial function and content are reduced (Conley et al., 2000; Short et al., 2005). However, this age associated decrease in mitochondrial content and function may also be due in part to reduced physical activity and not completely attributable to aging per se (Russ and Kent-Braun, 2004). Thus, lower mitochondrial function may play a role in the age-related slowing of gait speed.

In fact, worse skeletal muscle mitochondrial function in older adults has been linked with higher fatigability (Santanasto et al., 2014), lower physical function (Joseph et al., 2012) and slower gait speed (Bourdel-Marchasson et al., 2007). For example, Coen et al. showed that higher mitochondrial function was significantly associated with faster gait speed in higher functioning older adults (Coen et al., 2013). However, the relationship between mitochondrial function and walking performance has not been examined in older adults with both high and low levels of physical function. The purpose of this research was to examine the cross-sectional relationship between mitochondrial energetics, measured by ^{31}P magnetic resonance spectroscopy (MRS), and walking performance in older adults with a wide range of functional capacity.

2. Methods

2.1. Participants

Participants were from two studies, employing identical measures of mobility and mitochondrial capacity for oxidative phosphorylation. The higher functioning cohort was from the Study of Energy in Aging-Pilot (SEA) (Santanasto et al., 2014; Coen et al., 2013)

and lower functioning participants were from an ancillary study to the Lifestyle Interventions and Independence for Elders (LIFE) Study (Fielding et al., 2011).

SEA participants were community-dwelling ($n = 37$) men and women aged 70–89 years from the Pittsburgh, PA area and inclusion and exclusion criteria have been described in detail elsewhere (Santanasto et al., 2014; Coen et al., 2013). Briefly, inclusion criteria included body mass index 20–32 kg/m², ability to walk without an assistive device and free of basic activities of daily living disability. Exclusion criteria included history of hip fracture, heart attack, angioplasty, or heart surgery within the past 3 months, cerebral hemorrhage within the past 6 months, stroke within the past 12 months, or symptomatic cardiovascular or pulmonary disease. Participants were assessed at the magnetic resonance imaging (MRI) center for ³¹P MRS scan eligibility for ability to lie in a supine position for 1 h, no MR unsafe metal or other implants, bilateral joint replacements, and tattoos. The final analytical sample from SEA included 29 participants with complete MRS and 400 m walk data.

The LIFE Study was a multi-center randomized controlled trial designed to test the effectiveness of physical activity compared with health education on preventing mobility disability (Fielding et al., 2011; Pahor et al., 2014). Briefly, LIFE included sedentary adults aged 70–89, at high risk for mobility disability (Short Physical Performance Battery [SPPB, 0–12] score of ≤ 9) (Guralnik et al., 2000) but able to walk 400 m in <15 min. LIFE study recruitment began in March of 2010 and ended in December of 2011 for the full study. In May 2011, LIFE participants from the Pittsburgh field center were screened, and if eligible, invited to take part in an ancillary study visit prior to starting their intervention program. The ancillary visit included a ³¹P MRS scan, which had identical MR eligibility criteria to SEA. There were 91 LIFE participants randomized during this time and of these: 17 (18.7%) refused, 35 (38.5%) were ineligible (28 due to MR unsafe implants or bilateral knee/hip replacements) and 39 (42.9%) were eligible to participate in the MR ancillary study. Of the 39 eligible participants, 33 had useable MRS data, yielding a final LIFE analytic sample of 33. Thus, the final analytic sample included 29 SEA and 33 LIFE participants (total $n = 62$).

Both LIFE and SEA study protocols were approved by the University of Pittsburgh Institutional Review Board. All participants provided written informed consent.

2.2. Clinic examination and measurements

Participants completed clinic visits at the Health Studies Research Center at the University of Pittsburgh. Body height (cm) was measured using a wall-mounted stadiometer and body weight (kg) with a standard certified, calibrated scale, and used to calculate BMI (kg/m²). Participants completed demographic and self-reported health questionnaires. Questions were phrased in a similar manner between studies with one exception: history of arthritis. In SEA, the question asked about any history of arthritis, whereas LIFE asked about a doctor's visit in the past 6 months for arthritis or rheumatism. Diabetes was defined as either self-reported diagnosis, use of diabetic hypoglycemic medication or fasting blood glucose ≥ 126 mg/dL.

Lower extremity function was assessed using the SPPB, a widely used performance measure scored on a 0–12 point scale. The test includes 3 parts: a 4 m walk; 5 timed, repeated chair

stands; and a balance battery each worth 0–4 points (Guralnik et al., 2000). Seven-day free-living physical activity was measured in both studies; LIFE used the Actigraph™ accelerometer (model GT3X, ActiGraph, LLC), while SEA employed the SenseWear™ Pro armband (BodyMedia, Pittsburgh, PA). NHANES cut-points (Matthews et al., 2008) were used to categorize Actigraph counts, while the Sensewear's proprietary algorithm was used to calculate minutes per day spent in moderate and above (≥3 METs) intensity activities.

2.3. 400-Meter walk

Walk protocols for both studies were nearly identical (Coen et al., 2013; Fielding et al., 2011). The only difference was that LIFE permitted use of a single pronged cane. In both studies the test was conducted on a level ground 20-m course. Participants were instructed to walk at their usual pace, without overexertion for 10 laps (20 m up and back). Following the walk, participants from both studies were asked “Is anything bothering you?” and reported symptoms were recorded. Discomfort following the walk was defined as responding yes to this question. One SEA participant of the original 37 was excluded from analyses due to not completing the 400 m walk.

2.4. Determination of ATP_{max} by ³¹P MRS

MRS protocols were identical and both studies utilized the same MR magnet, technician and MRS analyst. Phosphocreatine (PCr) recovery after exercise (ATP_{max}) was used to quantify mitochondrial capacity for oxidative phosphorylation. ³¹P MRS has been validated by animal and human studies showing that ATP_{max} varies in direct proportion to oxidative enzyme activity of healthy muscle (Paganini et al., 1997) and mitochondrial content in human muscle (Conley et al., 2000). ATP_{max} has good reproducibility illustrated by previously published Bland Altman analysis from SEA (Santanasto et al., 2012).

The exercise protocol was performed in an MRI magnet (3T TIM Trio, Siemens' Medical System) (Santanasto et al., 2014; Coen et al., 2013). Participants laid supine with the right knee (unless contraindicated) elevated at ~30°. Straps were placed over the legs and a 2.5" surface RF coil tuned to ³¹P was placed over the quadriceps. Participants performed repeated voluntary, rapid, maximal isometric contractions (kicking) for two bouts (30 s and 36 s) followed by a 6-minute rest. The protocol was designed to deplete PCr by 33–66% without inducing acidosis (pH <6.8). A monoexponential fit of [PCr] recovery yields the recovery constant (k) for use in calculating ATP_{max}:

$$ATP_{max} = [PCr]_{rest} \cdot k_{PCr}$$

Previous analyses of human vastus lateralis muscle biopsies revealed that ATP content accounted for the range of PCr/ATP levels among participants aged 65–80 years (Conley et al., 2000). In contrast, PCr was stable (as was total creatine) and averaged 27 mM. Thus, we used 27 mM for [PCr]_{rest} (Santanasto et al., 2014; Coen et al., 2013). Finally, we determined pH from the chemical shift of the Pi peak relative to the PCr peak (Heineman et al., 1990).

2.5. Statistical analyses

The final analytic sample included 29 SEA and 33 LIFE participants with complete ATP_{max} and 400 m data (total $n = 62$). Baseline characteristics, means and standard deviations for continuous variables and frequencies and percents for categorical variables, were generated for each study. To test for between study differences, Wilcoxon rank-sum, chi-squared and Fischer's exact tests were used where appropriate.

To determine the relationship between ATP_{max} and 400 m walk time (s) multivariable linear regression was used. We present results for each group separately. Bivariate and multivariable models adjusted for age, sex, race, study and BMI were generated. The beta coefficients represent the difference in 400 m walk time (in seconds) per 1 SD higher ATP_{max} (0.14 mM atp/s). Since it has been shown that those with type 2 diabetes have impaired mitochondrial function (Kelley et al., 2002), we also examined the effect of diabetes on the relationship between ATP_{max} and 400 m walk time. Physical activity was considered last because it is a known determinant of mitochondrial function, as we have previously shown (Coen et al., 2013; Santanasto et al., 2015). All analyses were performed with SAS version 9.3.

3. Results

3.1. Baseline comparison of SEA and LIFE study participants

LIFE compared with SEA participants were significantly more overweight, less active, had lower SPPB scores, and slower 400 m walk times (Table 1). Of note, only one SEA participant had an SPPB score < 9, an inclusion criteria for LIFE. LIFE also contained a significantly larger proportion of females and African Americans as well as a higher prevalence of diabetes and fewer reporting consuming 6 or more drinks per (Table 1). Despite significantly lower physical function and activity levels, LIFE had similar ATP_{max} compared with SEA (0.55 ± 0.14 vs. 0.52 ± 0.14 mM ATP/s, $p = 0.31$).

In LIFE, 12 (36.4%) participants reported discomfort at the end of the walk compared with 5 (17.2%) from SEA (Table 1). More specifically, in LIFE, 3 participants reported back pain, 3 reported hip pain, 2 reported knee pain, 2 reported light headedness, 1 reported tiredness and foot pain, while 1 requested their straight cane due to general discomfort. In SEA, the 5 participants who reported discomfort reported the following symptoms: shortness of breath and back pain, knee and calf pain, back pain, hip and calf pain, and foot pain.

3.2. Relationship between ATP_{max} and 400 m walk time

Higher levels of ATP_{max} were significantly related to faster 400 m walk time in SEA ($\beta = -29.3$, $p = 0.02$), with ATP_{max} explaining 19% of the variance in walk time (Table 2, Fig. 1). However, no association was observed in LIFE ($\beta = 6.2$, $p = 0.74$, Table 2, Fig. 1). After adjustment for age, sex, race and BMI, the relationship between ATP_{max} and 400 m walk time in the SEA was attenuated slightly ($\beta = -24.8$, $p = 0.08$). Adding diabetes to the fully adjusted models had no effect on the relationship between ATP_{max} and walk time (SEA: $p = 0.95$; LIFE: $p = 0.52$ for diabetes parameter) and there was no interaction between ATP_{max} and diabetes on walking time in either cohort (SEA: $p > 0.99$; LIFE: $p = 0.15$). Physical

activity was uniformly low in LIFE and not associated with ATP_{max} ($r = -0.06$, $p = 0.75$), while it was in SEA ($r = 0.48$, $p < 0.01$), as we have previously shown (Coen et al., 2013; Santanasto et al., 2015).

4. Discussion

High ATP_{max} was associated with faster time to walk 400 m in higher functioning, active SEA participants, but not lower functioning, sedentary LIFE participants. This lack of an association is contrary to hypotheses generated from our previous work (Coen et al., 2013) as well as several other studies of older adults (Joseph et al., 2012; Bourdel-Marchasson et al., 2007; Hou et al., 2002). Namely, higher mitochondrial function measured by ^{31}P MRS was related to faster time to complete a get-up-and-go-test in French, lower functioning hospitalized ($n = 49$, aged 86.1 ± 5.3 years) and higher functioning community-dwelling older adults ($n = 28$, aged 74.5 ± 6.2 years) (Bourdel-Marchasson et al., 2007). Similarly, a muscle biopsy study in relatively younger (aged 62.0 ± 11.8) peripheral artery disease patients showed that higher mitochondrial function was related to longer walking time during a VO_2 max test (Hou et al., 2002). Importantly, both of the previously mentioned studies measured mitochondrial function in the gastrocnemius muscle (Bourdel-Marchasson et al., 2007; Hou et al., 2002), whereas the current study used the quadriceps. The conflicting results could be attributable to studying different muscle groups, as previous cross-sectional work suggests aging may affect locomotory muscles differently (Larsen et al., 2012). However, the vastus lateralis (VL) muscle, the muscle of interest in the current study, may be more susceptible to age and physical activity related changes compared to the tibialis anterior muscle (Larsen et al., 2012). Therefore, in theory the VL muscle would have been more closely associated with age related decreases in walking performance. Further, a study from Joseph et al. showed that participants with lower mitochondrial respiration rates and markers of biogenesis in permeabilized muscle fibers from the VL are also significantly more likely to have lower SPPB scores (Joseph et al., 2012). Although both are locomotory muscles of the lower leg, perhaps mitochondrial function in the gastrocnemius and tibialis anterior muscles undergo heterogeneous age-related changes possibly due to gait biomechanics. This issue requires further investigation in studies examining the relationship between walking performance and mitochondrial function in different muscle groups from the same individual. Further, longitudinal studies of different muscle groups are needed to truly understand the effects of age and physical activity on mitochondrial function.

Another key finding was that ATP_{max} levels were nearly identical between SEA and LIFE even though the LIFE participants were much less physically active and lower functioning. This conflicts with two studies showing that sedentary older adults have impaired mitochondrial function compared with active (Safdar et al., 2010) and a second finding that lower functioning older adults possess worse mitochondrial bioenergetics compared with higher functioning as measured by the SPPB (Joseph et al., 2012). These conflicting results may in part be explained by the different measures of mitochondrial function, as the two abovementioned studies used biopsy measures. However, ATP_{max} reflects in-vitro measures of mitochondrial function (Coen et al., 2013); perhaps ATP_{max} does not correlate as well with biopsy measures in lower function individuals. Future methodological work should investigate these associations in low functioning participants.

The inconsistencies concerning the relationship between ATP_{max} and walking performance could be attributable to our walking performance measure (400 m walk); however, lower functioning individuals walk closer to their maximal performance during a usual paced 400 m walk compared with higher functioning (Lange-Maia et al., 2015). Therefore, since ATP_{max} is highly related to VO_2 peak (Coen et al., 2013), a stronger relationship would have been expected in the lower functioning LIFE participants. Unless the LIFE participants had other impairments limiting walking performance, unrelated to oxidative capacity of the quadriceps, such as pain or joint stiffness. Indeed, although the difference did not reach statistical significance, over twice the proportion of LIFE participants reported discomfort, mainly due to pain, during the walk compared with SEA (36% vs. 17%).

There are several possible explanations for why ATP_{max} was unrelated to 400 m walk time in lower functioning participants. First, there may be differences in muscle mass that could affect walking time independent of ATP_{max} ; however LIFE was lacking a measure of muscle mass. The, the higher prevalence of discomfort and pain experience by LIFE participants during the walk may have caused them to slow down for reasons unrelated to mitochondrial function. Joint impairments (Gibbs et al., 1996), arthritis (Al-Zahrani and Bakheit, 2002), knee (Powers et al., 1997) and back pain (Rudy et al., 2007) are associated with slower walking speed or physical disability in older adults. Secondly, the LIFE Study was lacking a measure of mitochondrial efficiency (P/O), which is related to exercise efficiency in older adults (Conley et al., 2013). Finally, since discomfort and pain may evoke alterations to normal gait (Kuo and Donelan, 2010), it is plausible that those with both higher levels of ATP_{max} and slower walk times were biomechanically inefficient. Thus, these participants may be producing more energy (ATP) to walk at the same speed (or more slowly) than a biomechanically efficient individual. Indeed, higher energy cost of walking (VO_2 normalized to gait speed) is related to worse biomechanical gait parameters (Wert et al., 2010; Malatesta et al., 2003) and impaired mobility (Malatesta et al., 2003; Richardson et al., 2014; Schrack et al., 2010). This may cause a less biomechanically efficient individual to have a higher ATP_{max} than their activity level or walking speed would suggest, which may also partially explain the phenomenon of similar ATP_{max} levels observed in SEA compared with LIFE. However, we cannot rule out the mediating role of other factors related to VO_2 peak such as cardiopulmonary function. Further investigations are needed, particularly in lower functioning older adults, to further understand the interrelationships between ATP_{max} , gait biomechanics, energy cost of walking and walking performance.

Strengths of this study include a larger sample size compared with previous work examining the relationship between skeletal muscle mitochondrial energetics and walking performance in older adults and including a diverse population in terms of sex, race, function and physical activity levels. Mitochondrial function was measured directly and in vivo using ^{31}P MRS. Performance measures, as opposed to self-report, were used to quantify physical function and walking speed. Limitations include participants being from two separate studies; however, the study sites, primary outcome and predictor were identical. Muscle biopsies were not obtained in the LIFE cohort, so mitochondrial efficiency and other parameters could not be determined. The study was cross-sectional, thus no causal inferences can be made. Despite being the largest study to have examined these relationships to date, the sample size was still relatively small, which limited our ability to stratify by possible

mediating/confounding factors, particularly those that differed across the study populations, or test for interactions.

In conclusion, our study provides important and novel insights into the role of skeletal muscle mitochondrial capacity for oxidative phosphorylation in walking performance in older adults. Specifically, ATP_{max} (functional oxidative capacity of the quadriceps) was unrelated to walking times in lower functioning, sedentary participants and those with a wide range of function. However, higher mitochondrial function was related to faster walking times in higher functioning, active participants. This suggests that lower mitochondrial function may be a marker of early functional decline in higher functioning older adults. Further, mitochondrial function does not appear to be a limiting factor in lower functioning participants, who may slow for other reasons such as pain while ambulating. Larger studies examining other aspects mitochondrial energetics, energy cost and physical performance in older adults with wide age (e.g. aged 50–85) and physical function ranges are needed to further investigate these relationships.

Acknowledgments

SEA participants were recruited using the Pittsburgh Claude D. Pepper Older Americans Independence Center Research Registry (P30 AG024827).

Research investigators and funding for the LIFE Main Study

The Lifestyle Interventions and Independence for Elders Study is funded by a National Institutes of Health/National Institute on Aging Cooperative Agreement #U01 AG22376 and a supplement from the National Heart, Lung and Blood Institute 3U01AG022376-05A2S, and sponsored in part by the Intramural Research Program, National Institute on Aging, NIH.

The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (1 P30 AG028740), Wake Forest University (1 P30 AG21332), Tufts University (1P30AG031679), University of Pittsburgh (P30 AG024827), and Yale University (P30AG021342) and the NIH/NCRR CTSA at Stanford University (UL1 RR025744), Tufts University is also supported by the Boston Rehabilitation Outcomes Center (1R24HD065688-01A1).

LIFE investigators are also partially supported by the following: Dr. Thomas Gill (Yale University) is the recipient of an Academic Leadership Award (K07AG3587) from the National Institute on Aging.

Dr. Carlos Fragoso (Spirometry Reading Center, Yale University) is the recipient of a Career Development Award from the Department of Veterans Affairs.

Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No. 58–1950–0-014. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the U.S. Dept of Agriculture.

Administrative Coordinating Center, University of Florida, Gainesville, FL.

Marco Pahor, MD – Principal Investigator of the LIFE Study.

Jack M. Guralnik, MD, PhD – Co-Investigator of the LIFE Study (University of Maryland School of Medicine, Baltimore, MD).

Christiaan Leeuwenburgh, PhD.

Connie Caudle.

Lauren Crump, MPH.

Latonia Holmes.

Jocelyn Lee, PhD.

Ching-ju Lu, MPH.

Data Management, Analysis and Quality Control Center, Wake Forest University, Winston Salem, NC.

Michael E. Miller, PhD – DMAQC Principal Investigator.

Mark A. Espeland, PhD – DMAQC Co-Investigator.

Walter T. Ambrosius, PhD.

William Applegate, MD.

Daniel P. Beavers, PhD, MS.

Robert P. Byington, PhD, MPH, FAHA.

Delilah Cook, CCRP.

Curt D. Furberg, MD, PhD.

Lea N. Harvin, BS.

Leora Henkin, MPH, Med.

John Hepler, MA.

Fang-Chi Hsu, PhD.

Laura Lovato, MS.

Wesley Roberson, BSBA.

Julia Rushing, BSPH, MStat.

Scott Rushing, BS.

Cynthia L. Stowe, MPM.

Michael P. Walkup, MS.

Don Hire, BS.

W. Jack Rejeski, PhD.

Jeffrey A. Katula, PhD, MA.

Peter H. Brubaker, PhD.

Shannon L. Mihalko, PhD.

Janine M. Jennings, PhD.

National Institutes of Health, Bethesda, MD.

Evan C. Hadley, MD (National Institute on Aging).

Sergei Romashkan, MD, PhD (National Institute on Aging).

Kushang V. Patel, PhD (National Institute on Aging).

National Heart, Lung and Blood Institute, Bethesda, MD.

Denise Bonds, MD, MPH.

Field Centers.**Northwestern University, Chicago, IL.**

Mary M. McDermott, MD – Field Center Principal Investigator.

Bonnie Spring, PhD – Field Center Co-Investigator.

Joshua Hauser, MD – Field Center Co-Investigator.

Diana Kerwin, MD – Field Center Co-Investigator.

Kathryn Domanchuk, BS.

Rex Graff, MS.

Alvito Rego, MA.

Pennington Biomedical Research Center, Baton Rouge, LA.

Timothy S. Church, MD, PhD, MPH – Field Center Principal Investigator.

Steven N. Blair, PED (University of South Carolina).

Valerie H. Myers, PhD.

Ron Monce, PA-C.

Nathan E. Britt, NP.

Melissa Nauta Harris, BS.

Ami Parks McGucken, MPA, BS.

Ruben Rodarte, MBA, MS, BS.

Heidi K. Millet, MPA, BS.

Catrine Tudor-Locke, PhD, FACSM.

Ben P. Butitta, BS.

Sheletta G. Donatto, MS, RD, LDN, CDE.

Shannon H. Cocreham, BS.

Stanford University, Palo Alto, CA.

Abby C. King, PhD – Field Center Principal Investigator.

Cynthia M. Castro, PhD William L. Haskell, PhD.

Randall S. Stafford, MD, PhD Leslie A. Pruitt, PhD.

Kathy Berra, MSN, NP-C, FAAN.

Veronica Yank, MD.

Tufts University, Boston, MA.

Roger A. Fielding, PhD – Field Center Principal Investigator.

Miriam E. Nelson, PhD – Field Center Co-Investigator.

Sara C. Folta, PhD – Field Center Co-Investigator.

Edward M. Phillips, MD.

Christine K. Liu, MD.

Erica C. McDavitt, MS.

Kieran F. Reid, PhD, MPH.

Dylan R. Kirm, BS.

Evan P. Pasha, BS.

Won S. Kim, BS.

Vince E. Beard, BS.

Eleni X. Tsiroyannis, BS.

Cynthia Hau, BS, MPH.

University of Florida, Gainesville, FL.

Todd M. Manini, PhD – Field Center Principal Investigator.

Marco Pahor, MD – Field Center Co-Investigator.

Stephen D. Anton, PhD.

Susan Nayfield, MD.

Thomas W. Buford, PhD.

Michael Marsiske, PhD.

Bhanuprasad D. Sandesara, MD.

Jeffrey D. Knaggs, BS.

Megan S. Lorow, BS.

William C. Marena, MT, CCRC.

Irina Korytov, MD.

Holly L. Morris, MSN, RN, CCRC (Brooks Rehabilitation Clinical Research Center, Jacksonville, FL).

Margo Fitch, PT (Brooks Rehabilitation Clinical Research Center, Jacksonville, FL).

Floris F. Singletary, MS, CCC-SLP (Brooks Rehabilitation Clinical Research Center, Jacksonville, FL).

Jackie Causer, BSH, RN (Brooks Rehabilitation Clinical Research Center, Jacksonville, FL).

Katie A. Radcliff, MA (Brooks Rehabilitation Clinical Research Center, Jacksonville, FL).

University of Pittsburgh, Pittsburgh, PA.

Stephanie A. Studenski, MD, MPH – Field Center Co-Investigator.

Oscar Lopez, MD.

Neelesh K. Nadkarni, MD, PhD.

Kathy Williams, RN, BSEd, MHSA.

Mark A. Newman, PhD.

George Grove, MS.

Janet T. Bonk, MPH, RN.

Jennifer Rush, MPH.

Piera Kost, BA (deceased).

Diane G. Ives, MPH.

Wake Forest University, Winston Salem, NC.

Stephen B. Kritchevsky, Ph.D. – Field Center Principal Investigator.

Anthony P. Marsh, PhD – Field Center Co-Investigator.

Tina E. Brinkley, PhD.

Jamehl S. Demons, MD.

Kaycee M. Sink, MD, MAS.

Kimberly Kennedy, BA, CCRC.

Rachel Shertzer-Skinner, MA, CCRC.

Abbie Wrights, MS.

Rose Fries, RN, CCRC.

Deborah Barr, MA, RHED, CHES.

Yale University, New Haven, CT.

Thomas M. Gill, MD – Field Center Principal Investigator.

Robert S. Axtell, PhD, FACSM – Field Center Co-Investigator (Southern Connecticut State University, Exercise Science Department).

Susan S. Kashaf, MD, MPH (VA Connecticut Healthcare System).

Nathalie de Rekeneire, MD, MS.

Joanne M. McGloin, MDiv, MS, MBA.

Karen C. Wu, RN.

Denise M. Shepard, RN, MBA.

Barbara Fennelly, MA, RN.

Lynne P. Iannone, MS, CCRP.

Raeleen Mautner, PhD.

Theresa Sweeney Barnett, MS, APRN.

Sean N. Halpin, MA.

Matthew J. Brennan, MA.

Julie A. Bugaj, MS.

Maria A. Zenoni, MS.

Bridget M. Mignosa, AS LIFE.

Cognition Coordinating Center, Wake Forest University, Winston Salem, NC.

Jeff Williamson, MD, MHS – Center Principal Investigator.

Kaycee M Sink, MD, MAS – Center Co-Investigator.

Hugh C. Hendrie, MB, ChB, DSc (Indiana University).

Stephen R. Rapp, PhD.

Joe Verghese, MB, BS (Albert Einstein College of Medicine of Yeshiva University).

Nancy Woolard.

Mark Espeland, PhD.

Janine Jennings, PhD.

Valerie K. Wilson, MD.

Electrocardiogram Reading Center, University of Florida, Gainesville, FL.

Carl J. Pepine MD, MACC.

Mario Ariet, PhD.

Eileen Handberg, PhD, ARNP.

Daniel Deluca, BS.

James Hill, MD, MS, FACC.

Anita Szady, MD.

Spirometry Reading Center, Yale University, New Haven, CT.

Geoffrey L. Chupp, MD.

Gail M. Flynn, RCP, CRFT.

Thomas M. Gill, MD.

John L. Hankinson, PhD (Hankinson Consulting, Inc.)

Carlos A. Vaz Fragoso, MD.

Cost Effectiveness Analysis Center.

Erik J. Groessl, PhD (University of California, San Diego and VA San Diego Healthcare System).

Robert M. Kaplan, PhD (Office of Behavioral and Social Sciences Research, National Institutes of Health).

A preliminary version of this work was presented at the 2013 Annual Meeting of the Gerontological Society of America in New Orleans, Louisiana (Poster Session 510).

Funding

This work was supported by the National Institute on Aging/National Institutes of Health (grant number 1RC2AG036594-01 – SEA-P) as well The University of Pittsburgh, Center for Aging and Population Health: Pilot Grant Program and the Department of Epidemiology: Student Small Grant Program (LIFE-MITO). Adam Santanasto was supported by a Ruth L. Kirschstein National Research Service Award from the NIA (T32-AG-000181). Paul Coen is supported by a career development award from the National Institute on Aging (AG044437).

References

- Al-Zahrani KS, Bakheit AMO. A study of the gait characteristics of patients with chronic osteoarthritis of the knee. *Disabil Rehabil.* 2002; 24:275–280. <http://dx.doi.org/10.1080/09638280110087098>. [PubMed: 12004973]
- Bourdel-Marchasson I, Biran M, Dehaill P, et al. Muscle phosphocreatine post-exercise recovery rate is related to functional evaluation in hospitalized and community-living older people. *J Nutr Health Aging.* 2007; 11:7.
- Coen PM, Jubrias SA, Distefano G, et al. Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. *J Gerontol Ser A Biol Med Sci.* 2013; 68:447–455. <http://dx.doi.org/10.1093/gerona/gls196>.
- Conley KE, Jubrias SA, Cress ME, Esselman P. Exercise efficiency is reduced by mitochondrial uncoupling in the elderly. *Exp Physiol.* 2013; 98:768–777. <http://dx.doi.org/10.1113/expphysiol.2012.067314>. [PubMed: 23085769]
- Conley KE, Jubrias SA, Esselman PC. Oxidative capacity and ageing in human muscle. *J Physiol.* 2000; 526:203–210. <http://dx.doi.org/10.1111/j.1469-7793.2000.t01-1-00203.x>. [PubMed: 10878112]
- Fielding RA, Rejeski WJ, Blair S, et al. The lifestyle interventions and independence for elders study: design and methods. *J Gerontol Ser A Biol Med Sci.* 2011; 66A:1226–1237. <http://dx.doi.org/10.1093/gerona/glr123>.
- Fleg JL, Morrell CH, Bos AG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. *Circulation.* 2005; 112:674–682. <http://dx.doi.org/10.1161/circulationaha.105.545459>. [PubMed: 16043637]
- Gibbs J, Hughes S, Dunlop D, Singer R, Chang RW. Predictors of change in walking velocity in older adults. *J Am Geriatr Soc.* 1996; 44:126–132. [PubMed: 8576500]
- Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability. *J Gerontol Ser A Biol Med Sci.* 2000; 55:M221–M231. <http://dx.doi.org/10.1093/gerona/55.4.M221>.
- Heineman F, Eng J, Berkowitz B, Balaban R. NMR spectral analysis of kinetic data using natural lineshapes. *Magn Reson Med.* 1990; 13:490–497. [PubMed: 2325549]
- Hornyak V, VanSwearingen JM, Brach JS. Measurement of gait speed. *Top Geriatr Rehabil.* 2012; 28:27–32.
- Hou XY, Green S, Askew CD, Barker G, Green A, Walker PJ. Skeletal muscle mitochondrial ATP production rate and walking performance in peripheral arterial disease. *Clin Physiol Funct Imaging.* 2002; 22:226–232. <http://dx.doi.org/10.1046/j.1475-097X.2002.00423.x>. [PubMed: 12076351]
- Janssen I. Influence of sarcopenia on the development of physical disability: the cardiovascular health study. *J Am Geriatr Soc.* 2006; 54:56–62. <http://dx.doi.org/10.1111/j.1532-5415.2005.00540.x>. [PubMed: 16420198]
- Joseph AM, Adhietty PJ, Buford TW, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. *Aging Cell.* 2012; 11:801–809. <http://dx.doi.org/10.1111/j.1474-9726.2012.00844.x>. [PubMed: 22681576]
- Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. *Diabetes.* 2002; 51:2944–2950. <http://dx.doi.org/10.2337/diabetes.51.10.2944>. [PubMed: 12351431]
- Kuo AD, Donelan JM. Dynamic principles of gait and their clinical implications. *Phys Ther.* 2010; 90:157–174. <http://dx.doi.org/10.2522/ptj.20090125>. [PubMed: 20023002]
- Lange-Maia B, Newman A, Strotmeyer E, Harris T, Caserotti P, Glynn N. Performance on fast- and usual-paced 400-m walk tests in older adults: are they comparable? *Aging Clin Exp Res.* 2015; 27:309–314. <http://dx.doi.org/10.1007/s40520-014-0287-y>. [PubMed: 25373610]
- Larsen RG, Callahan DM, Foulis SA, Kent-Braun JA. Age-related changes in oxidative capacity differ between locomotory muscles and are associated with physical activity behavior. *Appl Physiol Nutr Metab.* 2012; 37:88–99. <http://dx.doi.org/10.1139/h11-135>. [PubMed: 22236246]

- Malatesta D, Simar D, Dauvilliers Y, et al. Energy cost of walking and gait instability in healthy 65- and 80-yr-olds. *J Appl Physiol* (1985). 2003; 95:2248–2256. <http://dx.doi.org/10.1152/jappphysiol.01106.2002>. [PubMed: 12882986]
- Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent in sedentary behaviors in the United States, 2003–2004. *Am J Epidemiol*. 2008; 167:875–881. <http://dx.doi.org/10.1093/aje/kwm390>. [PubMed: 18303006]
- Newman AB, Arnold AM, Sachs MC, et al. Long-term function in an older cohort—the cardiovascular health study all stars study. *J Am Geriatr Soc*. 2009; 57:432–440. <http://dx.doi.org/10.1111/j.1532-5415.2008.02152.x>. [PubMed: 19187412]
- Paganini AT, Foley JM, Meyer RA. Linear dependence of muscle phosphocreatine kinetics on oxidative capacity. *Am J Physiol Cell Physiol*. 1997; 272:C501–C510.
- Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. *J Am Med Assoc*. 2014; 311:2387–2396. <http://dx.doi.org/10.1001/jama.2014.5616>.
- Powers CM, Perry J, Hsu A, Hislop HJ. Are patellofemoral pain and quadriceps Femoris muscle torque associated with locomotor function? *Phys Ther*. 1997; 77:1063–1075. [PubMed: 9327821]
- Richardson, CA., Glynn, NW., Ferrucci, LG., Mackey, DC. Walking energetics, fatigability, and fatigue in older adults: the study of energy and aging pilot. *J Gerontol Ser A Biol Med Sci*. 2014. <http://dx.doi.org/10.1093/gerona/ glu146>
- Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiol Rev*. 1997; 77:731–758. [PubMed: 9234964]
- Rudy TE, Weiner DK, Lieber SJ, Slaboda J, Boston JR. The impact of chronic low back pain on older adults: a comparative study of patients and controls. *Pain*. 2007; 131:293–301. <http://dx.doi.org/10.1016/j.pain.2007.01.012>. [PubMed: 17317008]
- Russ DW, Kent-Braun JA. Is skeletal muscle oxidative capacity decreased in old age? *Sports Med*. 2004; 34:221–229. <http://dx.doi.org/10.2165/00007256-200434040-00002>. [PubMed: 15049714]
- Safdar A, Hamadeh MJ, Kaczor JJ, Raha S, deBeer J, Tarnopolsky MA. Aberrant mitochondrial homeostasis in the skeletal muscle of sedentary older adults. *PLoS One*. 2010; 5:e10778. <http://dx.doi.org/10.1371/journal.pone.0010778>. [PubMed: 20520725]
- Santanasto, AJ., Glynn, NW., Jubrias, SA., et al. Skeletal muscle mitochondrial function and fatigability in older adults. *J Gerontol Ser A Biol Med Sci*. 2014. <http://dx.doi.org/10.1093/gerona/ glu134>
- Santanasto AJ, Glynn NW, Jubrias SA, et al. Skeletal muscle mitochondrial function and fatigability in older adults. *J Gerontol Ser A Biol Med Sci*. 2015; 70:1379–1385. <http://dx.doi.org/10.1093/gerona/ glu134>.
- Santanasto, AJ., Simonsick, EM., Ferrucci, LM., et al. Perceived fatigability Is associated with mobility and performance in older adults; Gerontological Society of America, National Meeting; San Diego, CA. 2012.
- Schrack JA, Simonsick EM, Ferrucci L. The energetic pathway to mobility loss: an emerging new framework for longitudinal studies on aging. *J Am Geriatr Soc*. 2010; 58:S329–S336. <http://dx.doi.org/10.1111/j.1532-5415.2010.02913.x>. [PubMed: 21029063]
- Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. *Proc Natl Acad Sci U S A*. 2005; 102:5618–5623. <http://dx.doi.org/10.1073/pnas.0501559102>. [PubMed: 15800038]
- Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *JAMA*. 2011; 305:50–58. <http://dx.doi.org/10.1001/jama.2010.1923>. [PubMed: 21205966]
- Wert DM, Brach J, Perera S, VanSwearingen JM. Gait biomechanics, spatial and temporal characteristics, and the energy cost of walking in older adults with impaired mobility. *Phys Ther*. 2010; 90:977–985. <http://dx.doi.org/10.2522/ptj.20090316>. [PubMed: 20488977]




Fig. 1.

ATP_{max} is defined as phosphocreatine recovery in the quadriceps following an acute bout of exercise measured by ³¹P magnetic resonance spectroscopy. Unadjusted *p*-values and bivariate *r*² values for the relationship between ATP_{max} and 400 m walk time were as follows: A.) *r*² = 0.19, *p* = 0.02 for SEA and B.) *r*² < 0.01, *p* = 0.75 for LIFE.

Table 1

Characteristics by Study and in Combination.

	SEA (<i>n</i> = 29) Mean (SD) or <i>N</i> (%)	LIFE (<i>n</i> = 33) Mean (SD) or <i>N</i> (%)	<i>p</i> -Value for between study difference
Age, yrs	78.6 (5.0)	76.6 (5.5)	0.14
Sex, female	13 (44.8)	25 (75.8)	0.01
Race, white	27 (93.1)	16 (48.5)	<0.01
BMI, kg/m ²	26.0 (2.7)	30.8 (5.4)	<0.01
Smoker, current or former	10 (34.5)	9 (27.3)	0.54
Alcohol, 6+ drinks/week	8 (27.6)	2 (6.1)	0.04
Diabetes	1 (3.5)	9 (27.3)	0.01
Myocardial infarction	3 (10.3)	1 (3.0)	0.33
Chronic obstructive pulmonary disease	1 (3.5)	3 (9.1)	0.62
Arthritis	9 (31.0)	6 (18.2)	0.24
Moderate and above activity, min/day	77.4 (73.3)	1.6 (2.2)	<0.01
SPPB, 0–12	10.8 (1.4)	7.8 (1.2)	<0.01
400 m walk time, s	343.8 (65.5)	466.9 (110.1)	<0.01
Discomfort at end of 400 m walk, yes	5 (17.2)	12 (36.4)	0.09
ATP _{max} , mM/s	0.52 (0.14)	0.55 (0.14)	0.31

Table 2Association between ATP_{max} and time to walk 400 m by Study and in Combination.

Model	Beta, s ^b (per 0.14 mM/ATP/s)	SE	p-Value
SEA (<i>n</i> = 29) – unadjusted	-29.3	11.6	0.02
SEA – adjusted ^a	-24.8	13.3	0.08
LIFE (<i>n</i> = 33) – unadjusted	6.2	19.5	0.75
LIFE – adjusted ^a	26.0	16.0	0.11

SE: standard error.

^aAdjusted for age, race, sex and BMI.^bBeta coefficients represent the difference in 400 m walk time (in seconds) per 1 SD higher ATP_{max} (0.14 mM atp/s).